ASX - By Stock
|
PNV |
Re:
30th June 2025 Share Price Prediction
|
|
MiddleDistance
|
142 |
39K |
0 |
30/06/24 |
30/06/24 |
ASX - By Stock
|
142
|
39K
|
0
|
|
ASX - By Stock
|
PNV |
Re:
Ann: 1H23 Indicative Trading Result (unaudited)
|
|
MiddleDistance
|
130 |
48K |
18 |
16/01/23 |
16/01/23 |
ASX - By Stock
|
130
|
48K
|
18
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
MiddleDistance
|
2.9K |
1.2M |
19 |
22/12/22 |
22/12/22 |
ASX - By Stock
|
2.9K
|
1.2M
|
19
|
|
ASX - By Stock
|
PNV |
Re:
30th June 2023 Share Price Prediction
|
|
MiddleDistance
|
118 |
41K |
1 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
118
|
41K
|
1
|
|
ASX - By Stock
|
SQ2 |
Re:
Block Share Price at end of 2022
|
|
MiddleDistance
|
230 |
90K |
1 |
06/02/22 |
06/02/22 |
ASX - By Stock
|
230
|
90K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
MiddleDistance
|
47 |
14K |
2 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
47
|
14K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: DARRT-2 Study Receives IND Approval from FDA
|
|
MiddleDistance
|
14 |
6.7K |
2 |
05/07/21 |
05/07/21 |
ASX - By Stock
|
14
|
6.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: DARRT-2 Study Receives IND Approval from FDA
|
|
MiddleDistance
|
14 |
6.7K |
3 |
05/07/21 |
05/07/21 |
ASX - By Stock
|
14
|
6.7K
|
3
|
|
ASX - By Stock
|
PNV |
Re:
30th June 2022 Share Price Prediction
|
|
MiddleDistance
|
113 |
34K |
0 |
01/07/21 |
01/07/21 |
ASX - By Stock
|
113
|
34K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep global webcast slides
|
|
MiddleDistance
|
29 |
12K |
2 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
29
|
12K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep global webcast slides
|
|
MiddleDistance
|
29 |
12K |
2 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
29
|
12K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Ann: TACTI-002 & INSIGHT-004 data to be presented at ASCO
|
|
MiddleDistance
|
260 |
105K |
9 |
20/05/21 |
20/05/21 |
ASX - By Stock
|
260
|
105K
|
9
|
|
ASX - By Stock
|
PNV |
Re:
Short Activity in PNV
|
|
MiddleDistance
|
6.8K |
2.1M |
3 |
28/04/21 |
28/04/21 |
ASX - By Stock
|
6.8K
|
2.1M
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Operational Update
|
|
MiddleDistance
|
8 |
3.5K |
4 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
8
|
3.5K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pre-Clinical Breakthrough Discovery Set to Expand Pipeline
|
|
MiddleDistance
|
11 |
5.3K |
9 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
11
|
5.3K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
LAG-3
|
|
MiddleDistance
|
42 |
19K |
14 |
03/12/20 |
03/12/20 |
ASX - By Stock
|
42
|
19K
|
14
|
|
ASX - By Stock
|
NOX |
BMS NOX to partner on pilot study
|
|
MiddleDistance
|
7 |
2.4K |
9 |
25/11/20 |
25/11/20 |
ASX - By Stock
|
7
|
2.4K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep to present TACTI-002 phase 2 data at SITC 2020
|
|
MiddleDistance
|
27 |
10K |
8 |
04/11/20 |
04/11/20 |
ASX - By Stock
|
27
|
10K
|
8
|
|
ASX - By Stock
|
PNV |
Re:
Ann: Taiwan FDA Approval for PolyNovo
|
|
MiddleDistance
|
51 |
17K |
11 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
51
|
17K
|
11
|
|
ASX - By Stock
|
IMM |
Re:
Ann: COVID-19 phase 2 investigator initiated trial commences
|
|
MiddleDistance
|
35 |
17K |
1 |
23/10/20 |
23/10/20 |
ASX - By Stock
|
35
|
17K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
ESMO abstract release
|
|
MiddleDistance
|
114 |
47K |
5 |
18/09/20 |
18/09/20 |
ASX - By Stock
|
114
|
47K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Recruitment of stage 1 of part B in TACTI-002 study complete
|
|
MiddleDistance
|
23 |
7.8K |
0 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
23
|
7.8K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Recruitment of stage 1 of part B in TACTI-002 study complete
|
|
MiddleDistance
|
23 |
7.8K |
3 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
23
|
7.8K
|
3
|
|
ASX - By Stock
|
PNV |
Re:
30th June 2021 Share Price Prediction
|
|
MiddleDistance
|
359 |
140K |
1 |
01/07/20 |
01/07/20 |
ASX - By Stock
|
359
|
140K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
encouraging progress !
|
|
MiddleDistance
|
58 |
20K |
13 |
02/06/20 |
02/06/20 |
ASX - By Stock
|
58
|
20K
|
13
|
|
ASX - By Stock
|
IMM |
Re:
Very Disappointing
|
|
MiddleDistance
|
53 |
14K |
12 |
30/04/20 |
30/04/20 |
ASX - By Stock
|
53
|
14K
|
12
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
|
|
MiddleDistance
|
96 |
49K |
25 |
26/03/20 |
26/03/20 |
ASX - By Stock
|
96
|
49K
|
25
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep reports supportive efficacy data from AIPAC study
|
|
MiddleDistance
|
116 |
55K |
8 |
25/03/20 |
25/03/20 |
ASX - By Stock
|
116
|
55K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
* interview
|
|
MiddleDistance
|
26 |
12K |
19 |
25/03/20 |
25/03/20 |
ASX - By Stock
|
26
|
12K
|
19
|
|
ASX - By Stock
|
IMM |
Re:
* interview
|
|
MiddleDistance
|
26 |
12K |
0 |
24/03/20 |
24/03/20 |
ASX - By Stock
|
26
|
12K
|
0
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Change of Director's Interest Notice - Mr Chamberlain
|
|
MiddleDistance
|
45 |
22K |
5 |
19/03/20 |
19/03/20 |
ASX - By Stock
|
45
|
22K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
News: IMM Immutep Says FDA Approves Investigational New Drug Application For Eftilagimod Alpha
|
|
MiddleDistance
|
22 |
12K |
5 |
10/03/20 |
10/03/20 |
ASX - By Stock
|
22
|
12K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Clinical Update & Results Global Webcast Slides
|
|
MiddleDistance
|
88 |
1.5M |
1 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
88
|
1.5M
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Clinical Update & Results Global Webcast Slides
|
|
MiddleDistance
|
88 |
1.5M |
0 |
06/03/20 |
06/03/20 |
ASX - By Stock
|
88
|
1.5M
|
0
|
|
ASX - By Stock
|
IMM |
Re:
eerily comfortable.....
|
|
MiddleDistance
|
142 |
102K |
5 |
15/02/20 |
15/02/20 |
ASX - By Stock
|
142
|
102K
|
5
|
|
ASX - By Stock
|
APT |
Re:
Afterpay Valuation
|
|
MiddleDistance
|
6.8K |
2.7M |
1 |
17/01/20 |
17/01/20 |
ASX - By Stock
|
6.8K
|
2.7M
|
1
|
|